Sphera Funds Management’s BridgeBio Pharma BBIO Stock Holding History

Sphera Funds Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-130,000	Closed	-$6.75M	–	102
2025 Q3	$6.75M	Buy	+130,000	New	+$6.34M	1.42%	19
2024 Q3	–	Sell	-204,600	Closed	-$5.18M	–	121
2024 Q2	$5.18M	Buy	204,600 +154,600	+309%	+$4.23M	0.71%	47
2024 Q1	$1.55M	Buy	+50,000	New	+$1.7M	0.22%	87
2023 Q3	–	Sell	-130,000	Closed	-$2.24M	–	88
2023 Q2	$2.24M	Sell	130,000 -70,000	-35%	-$1.05M	0.35%	69
2023 Q1	$3.32M	Buy	+200,000	New	+$2.33M	0.55%	54

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Sphera Funds Management's BBIO Position: Q2 2026 in Review

Sphera Funds Management increased its BridgeBio Pharma (BBIO) stake by 0.04% in Q2 2026, buying an estimated $7K and bringing the position to 245,346 shares worth $18.3M. The position accounts for 2.38% of the portfolio, ranked #11.

Sphera Funds Management first reported a position in BBIO in Q4 2020 and has held it in 16 quarters since. The position peaked at $24.8M in Q4 2024. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Sphera Funds Management held 245,346 shares of BridgeBio Pharma worth $18.3M as of Q2 2026.
Sphera Funds Management bought 100 BridgeBio Pharma shares in Q2 2026, an estimated $7K.
BridgeBio Pharma made up 2.38% of Sphera Funds Management's portfolio in Q2 2026, its #11 holding.
Sphera Funds Management first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 16 quarters since.
Sphera Funds Management's BridgeBio Pharma position peaked at $24.8M in Q4 2024.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.